{"id":"W3012894524","doi":"10.1007/s13555-020-00367-x","title":"Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials","year":2020,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":59,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research; Guenther Dermatology Research Centre","funders":"Cilag; LEO Pharma; Mitsubishi Tanabe Pharma Corporation; Sanofi; Kyowa Hakko Kirin; Biogen; Pfizer; Incyte; Fresenius Medical Care North America; Sun Pharma; Dermira; Samsung; UCB Pharma; Valeant Pharmaceuticals International; Medac; Baxalta; Hexal AG; Celgene; Regeneron Pharmaceuticals; Teva Pharmaceutical Industries; Amgen; Galderma; Eli Lilly and Company; GlaxoSmithKline","keywords":"Ixekizumab; Medicine; Dosing; Dermatology Life Quality Index; Psoriasis; Psoriasis Area and Severity Index; Imputation (statistics); Internal medicine; Randomized controlled trial; Quality of life (healthcare); Tolerability; Adverse effect; Dermatology; Secukinumab; Psoriatic arthritis","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008219418,0.0003144697,0.002820503,0.0000607933,0.0001481127,0.0000249554,0.0001468299,0.000360257,0.00006338365],"category_scores_gemma":[0.0007817329,0.0001890457,0.0002050548,0.0001289117,0.0003562187,0.00009593211,0.00005931009,0.0001922879,0.00001158683],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000007940145,"about_ca_system_score_gemma":0.00005604744,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001351879,"about_ca_topic_score_gemma":0.00003700644,"domain_scores_codex":[0.9955465,0.002608283,0.001074273,0.000458768,0.00004684707,0.0002653744],"domain_scores_gemma":[0.9924104,0.006894773,0.0003883344,0.0002271325,0.00003612004,0.00004328827],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9421729,0.0002392231,0.002575203,0.00001149798,0.003352707,0.0000497656,0.007664549,0.00001195027,0.003614033,0.0005652264,0.0002895237,0.03945342],"study_design_scores_gemma":[0.976521,0.0002996383,0.01334953,0.00007136117,0.0005792592,0.00008139008,0.0002098704,0.00002364058,0.006310997,0.001007467,0.001277293,0.0002685262],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9540812,0.04014156,0.0001135528,0.002961902,0.0002729906,0.001910778,0.0003858478,0.00002802962,0.0001041512],"genre_scores_gemma":[0.978789,0.01953317,0.00005231987,0.001240787,0.0000437886,0.00009923927,0.0001918761,0.00001583613,0.00003397178],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0391849,"threshold_uncertainty_score":0.770906,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03507305455433154,"score_gpt":0.2892764760050546,"score_spread":0.2542034214507231,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}